DelveInsight’s, “Systemic Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Systemic Sclerosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Systemic Sclerosis Pipeline Outlook
Key Takeaways from the Systemic Sclerosis Pipeline Report
Stay ahead with the most recent pipeline outlook for Systemic Sclerosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Systemic Sclerosis Treatment Drugs
Systemic Sclerosis Emerging Drugs Profile
Iloprost is a stable analogue of PGI2 and a potent prostacyclin (IP) receptor agonist. By mimicking PGI2, it is a vasodilator and inhibitor of platelet activation and fibrosis. Iloprost stimulates generation of cAMP by binding to the IP receptor, thereby affecting phospholipase activity and cytosolic calcium levels in platelets, fibroblasts, and endothelial cells. It is a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed and investigated in Phase III stage of development for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc).
ECCS-50 (Cytori stem cell therapy) is a new treatment intended for the treatment of moderate to severe hand problems in people with scleroderma. It involves taking stem cells (a cell with the potential to become any cell type) from patient’s fat tissue and reinjecting these cells into the hands. ECCS 50 are adipose derived stem and regenerative cells (ADRCs) taken from the patient’s own tissue and prepared using Cytori’s cellulation system before administration. ADRCs can be used to repair and regenerate a range of damaged or diseased tissue types by differentiation of the ASRCs along the specific cell lineage, thereby replacing the damaged or missing tissue.
Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability profiles without evidence of immunosuppression.
EHP-101 is an oral formulation of VCE-004.8, a synthetic aminoquinone derivative of CBD with dual peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid receptor type 2 (CB2) agonist activity. Both receptors are therapeutic targets for SSc. EHP-101 also modulates the hypoxia inducible factor (HIF) pathway, expanding the rationale for its development as a novel SSc drug. It is currently in phase II stage of development and is being developed by Emerald Health Pharmaceuticals.
The Systemic Sclerosis Pipeline Report Provides Insights into
Explore groundbreaking therapies and clinical trials in the Systemic Sclerosis Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Systemic Sclerosis Drugs
Systemic Sclerosis Companies
Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others.
Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Systemic Sclerosis Products have been categorized under various Molecule types such as
Unveil the future of Systemic Sclerosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Systemic Sclerosis Market Drivers and Barriers
Scope of the Systemic Sclerosis Pipeline Report
Get the latest on Systemic Sclerosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Systemic Sclerosis Companies, Key Products and Unmet Needs
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight
